Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome
Open Access
- 23 August 2021
- journal article
- research article
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 13 (3), 308-319
- https://doi.org/10.4274/jcrpe.galenos.2021.2020.0228
Abstract
Objective:To investigate clinical characteristics and response to growth hormone (GH) treatment in patients with Prader-Willi syndrome (PWS) in Turkey.Methods:The data of 52 PWS patients from ten centers was retrospectively analyzed. A nation-wide, web-based data system was used for data collection. Demographic, clinical, genetic, and laboratory data and follow-up information of the patients were evaluated.Results:The median age of patients at presentation was 1.5 years, and 50% were females. Genetic analysis showed microdeletion in 69.2%, uniparental disomy in 11.5%, imprinting defect in 1.9% and methylation abnormality in 17.3%. Hypotonia (55.7%), feeding difficulties (36.5%) and obesity (30.7%) were the most common complaints. Cryptorchidism and micropenis were present in 69.2% and 15.3% of males, respectively. At presentation, 25% had short stature, 44.2% were obese, 9.6% were overweight and 17.3% were underweight. Median age of obese patients was significantly higher than underweight patients. Central hypothyroidism and adrenal insufficiency were present in 30.7% and 4.7%, respectively. Hypogonadism was present in 75% at normal age of puberty. GH treatment was started in 40% at a mean age of 4.7±2.7 years. After two years of GH treatment, a significant increase in height SDS was observed. However, body mass index (BMI) standard deviation (SDS) remained unchanged.Conclusion:The most frequent complaints were hypotonia and feeding difficulty at first presentation. Obesity was the initial finding in 44.2%. GH treatment was started in less than half of the patients. While GH treatment significantly increased height SDS, BMI SDS remained unchanged, possibly due to the relatively older age at GH start.Keywords
This publication has 51 references indexed in Scilit:
- Endocrine manifestations and management of Prader-Willi syndromeInternational Journal of Pediatric Endocrinology, 2013
- Growth Hormone Research Society Workshop Summary: Consensus Guidelines for Recombinant Human Growth Hormone Therapy in Prader-Willi SyndromeJournal of Clinical Endocrinology & Metabolism, 2013
- A systematic review and meta-analysis to revise the Fenton growth chart for preterm infantsBMC Pediatrics, 2013
- Assessment of central adrenal insufficiency in children and adolescents with Prader–Willi syndromeClinical Endocrinology, 2012
- Nutritional phases in Prader–Willi syndromeAmerican Journal of Medical Genetics Part A, 2011
- Thyroid axis dysfunction in patients with Prader‐Willi syndrome during the first 2 years of lifeClinical Endocrinology, 2010
- Long-Term Growth Hormone Therapy Changes the Natural History of Body Composition and Motor Function in Children with Prader-Willi SyndromeJournal of Clinical Endocrinology & Metabolism, 2010
- Sudden death in growth hormone–treated children with Prader-Willi syndromeThe Journal of Pediatrics, 2004
- Towards a Consensus on the Definition of Idiopathic Short StatureHormone Research, 1996
- Prader‐Willi syndrome: Current understanding of cause and diagnosisAmerican Journal of Medical Genetics, 1990